DCPH Stock Doubles on Late-Stage Drug Data

Just last month Deutsche Bank called the stock's eventual pop

Digital Content Manager
Aug 13, 2019 at 9:52 AM
facebook twitter linkedin

The shares of biotech name Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) have more than doubled this morning after the durgmaker announced that its lead treatment, ripretinib, met its main goal during a late-stage study in patients with stomach cancer. The stock has shot up 100% at $39.95, trading right back near its June 2018 record highs, and set for its best day ever.

Just yesterday, DCPH took a massive slide, bottoming out at seven-month lows, and was struggling right below the year-to-date breakeven. point. This plummet comes just days after the stock tried to rally off a second-quarter earnings win earlier this month, only to be met with resistance at its 200-day moving average. Today, however, the equity is set to close atop this trendline, with only one other close north of here notched since last October. 

Analysts have had high hopes for Deciphera even before today's surge, made evident by its consensus 12-month target price of $45.50, which still holds a slight premium to the stock's current perch. What's more, all but one analyst has doled out a "strong buy" rating to the equity, with the holdout calling it a "strong sell." In fact, last month Deutsche Bank called the stock's pop, initiating coverage with a $42 price target and a "buy" rating. 

While short interest has been declining, down 14.3% in the last two reporting periods, the 3.09 million shares sold short still represents a healthy 20.5% of the stock's available float. Considering that it would still take over two weeks to buy back all these bearish bets at DCPH's average pace of trading, short covering tailwinds could still occur.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!



Special Offers from Schaeffer's Trading Partners